![Thomson Reuters](https://static.lse.co.uk/images/news-logos/thomson-reuters-news-logo.png)
Hikma accuses Amarin of suppressing generic versions of heart pill
Hikma claims Amarin used exclusive agreements with suppliers to frustrate generic rivals
*Read moreFri, 04th Sep 2015 11:52
Hikma claims Amarin used exclusive agreements with suppliers to frustrate generic rivals
*Read moreFriday 17 February | |
Allianz Technology Trust PLC | Full Year Results |
Kingspan Group PLC | Full Year Results |
NatWest Group PLC | Full Year Results |
Pod Point Group Holdings PLC | Full Year Results |
Segro PLC | Full Year Results |
Monday 20 February | |
Bank of Cyprus Holdings PLC | Full Year Results |
Georgia Capital PLC | Full Year Results |
Goldplat PLC | Full Year Results (TBC) |
LungLife AI Inc | Full Year Results |
Tristel PLC | Half Year Results |
Wilmington PLC | Half Year Results |
Tuesday 21 February | |
Antofagasta PLC | Full Year Results |
BHP Group Ltd | Half Year Results |
Blancco Technology Group PLC | Half Year Results |
Finsbury Food Group PLC | Half Year Results |
HSBC Holdings PLC | Full Year Results |
InterContinental Hotels Group PLC | Full Year Results |
Safestore Holdings PLC | Trading Statement |
Smith & Nephew PLC | Full Year Results |
Springfield Properties PLC | Half Year Results |
Sylvania Platinum Ltd | Half Year Results |
Trifast PLC | Trading Statement |
Wednesday 22 February | |
Avingtrans PLC | Half Year Results |
City of London Investment Group PLC | Half Year Results |
Conduit Holdings Ltd | Full Year Results |
Liberty Global PLC | Full Year Results |
Lloyds Banking Group PLC | Full Year Results |
Primary Health Properties PLC | Full Year Results |
Renewables Infrastructure Group Ltd | Full Year Results |
Rio Tinto PLC | Full Year Results |
Synectics PLC | Full Year Results |
TBC Bank Group PLC | Full Year Results |
Transense Technologies PLC | Half Year Results |
Thursday 23 February | |
Anglo American PLC | Full Year Results |
Arbuthnot Banking Group PLC | Trading Statement |
BAE Systems PLC | Full Year Results |
Bluefield Solar Income Fund Ltd | Half Year Results |
Drax Group PLC | Full Year Results |
Driver Group PLC | Full Year Results |
Genus PLC | Half Year Results |
Hays PLC | Half Year Results |
Hikma Pharmaceuticals PLC | Full Year Results |
Howden Joinery Group PLC | Full Year Results |
Macfarlane Group PLC | Full Year Results |
Made Tech Group PLC | Half Year Results |
Mondi PLC | Full Year Results |
Morgan Sindall Group PLC | Full Year Results |
Pantheon International PLC | Half Year Results |
Rolls-Royce Holdings PLC | Full Year Results |
Serco Group PLC | Full Year Results |
Spectris PLC | Full Year Results |
Versarien PLC | Full Year Results |
WPP PLC | Full Year Results |
Copyright 2023 Alliance News Ltd. All Rights Reserved. |
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:
Read more(Sharecast News) - Hikma Pharmaceuticals revealed on Wednesday that non-executive director Deneen Vojta had acquired 1,000 ordinary shares in the FTSE 250-listed drugmaker.
Read more(Alliance News) - Arecor Therapeutics PLC on Thursday said it transferred development activities for the ready-to-use injectable medicine AT307 to Hikma Pharmaceuticals PLC, and regained rights on AT282 after a product portfolio review.
Read moreFTSE 100 up 1.4%, FTSE 250 adds 1.5%
*Read more(Alliance News) - Hikma Pharmaceuticals PLC on Tuesday said it launched an authorised generic version of the Xyrem sodium oxybate prescription medicine in the US for treating narcolepsy.
Read more(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning, Monday and late Friday:
Read more(Alliance News) - Stock prices in London made a strong start to the new year on Tuesday, despite weak Chinese data and the UK suffering a fresh wave of rail strikes.
Read more(Alliance News) - Stocks in London are expected to start a new year on the front foot on Tuesday, after a mixed session in Asia amid weak Chinese economic data.
Read more(Sharecast News) - Hikma Pharmaceuticals has launched an authorised generic version of Jazz Pharmaceuticals' 'Xyrem 1', or sodium oxybate oral solution, it announced on Tuesday.
Read more(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:
Read more(Sharecast News) - RBC Capital Markets initiated coverage of Hikma Pharmaceuticals on Tuesday at 'outperform' with a 1,750p price target.
Read more(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:
Read more(Sharecast News) - Credit Suisse has initiated coverage of Hikma Pharmaceuticals with an 'outperform' rating.
Read more